NCT07470203 2026-03-13
Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer
Peking University Cancer Hospital & Institute
Not yet recruiting
Clinical Trials
10 trialsNCT06754059 2025-01-01
Pyrotinib Combined With Trastuzumab for Maintenance Therapy After First-line TH (P) Therapy for HER2+ABC
Fujian Medical University Union Hospital
Recruiting
NCT05856383 2023-05-12
HER2-VIP
Zhejiang Cancer Hospital
Recruiting
NCT05764941 2023-03-27
Inetetamab Combined With Pyrotinib and Vinorelbine as First-line to Third-line Treatment for HER2-positive Metastatic Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Unknown
NCT05561686 2022-09-30
Real-world Study of Pyrotinib in Neoadjuvant Therapy for HER2-positive Breast Cancer
Hunan Cancer Hospital
Unknown
NCT05030519 2022-03-02
A Study of Diarrhea and Intestinal Flora Changes Caused by Pyrotinib in Breast Cancer
Zhejiang Cancer Hospital
Unknown
NCT04899128 2021-05-24
Treatment With Pyrotinib-Based Therapy in Lapatinib Resistant HER2-Positive Metastatic Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Unknown
NCT04756921 2021-02-16
18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response
Fudan University
Completed
NCT04683445 2020-12-24
Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Unknown
NCT04609540 2020-12-16
Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC
Shandong Cancer Hospital and Institute
Unknown